Transient Pharma AB Joins SmiLe as New Incubator Company

SmiLe is very pleased to announce the addition of Transient Pharma AB to our incubator program. Transient Pharma is dedicated to the development of innovative systemic anti-inflammatory treatments, focusing initially on gastrointestinal inflammatory disorders and curbing the excessive inflammation during acute infections.

Transient Pharma´s groundbreaking research, originating from Professor Artur Schmidtchen’s lab at Lund University, has led to the development of TIM-03, a proprietary peptide with promising therapeutic potential. The peptide has demonstrated multifunctional properties consisting of strong anti-inflammatory effects (published in Nature Communications) and antimicrobial effects both in vitro and in vivo.

The mode of action is well understood, indicating that TIM-03 holds significant commercial potential for treating multiple inflammatory diseases, presenting a potentially broad pipeline opportunity. 

”We are delighted to welcome yet another pharmaceutical development company to our incubator program. In addition, we are happy to have CEO Helene Hartman returning with a new company, a highly motivated leader who has already proven her capability in fostering the growth of startup companies and navigating the intricate landscape of drug development,” says Ulrika Ringdahl, COO of SmiLe Incubator. 

Photo: Professor Artur Schmitchen and CEO Helene Hartman.